drugset / Trial / NCT07384234
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.
Timeline
- Start
- 2026-01-31
- Primary completion
- 2028-12-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | S-1 | Small molecule | — | — |
| Background | Retlirafusp alfa | Protein / enzyme biologic | 1800 mg | — |